Evidence map›Paper›PMID 32530737›Full record

ArticleVirulence2020

A novel biosafety level 2 compliant tuberculosis infection model using a Δ

Masanori Asai, Yanwen Li, John Spiropoulos, William Cooley, David Everest, Brian D Robertson, Paul R Langford, Sandra M Newton

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Virulence · 2022
    Article
  6. Innate Immune Responses ofFrontiers in cellular and infection microbiology · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Masanori AsaiSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London , London, UK.
Yanwen LiSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London , London, UK.
John SpiropoulosDepartment of Pathology, Animal and Plant Health Agency , Addlestone, UK.ORCID 0000-0003-0119-8920
William CooleyDepartment of Pathology, Animal and Plant Health Agency , Addlestone, UK.
David EverestDepartment of Pathology, Animal and Plant Health Agency , Addlestone, UK.
Brian D RobertsonMRC Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London , London, UK.ORCID 0000-0001-5785-5307
Paul R LangfordSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London , London, UK.
Sandra M NewtonSection of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London , London, UK.ORCID 0000-0001-6545-9558
Imperial College London · GBAnimal and Plant Health Agency · GB

Funding

Biotechnology and Biological Sciences Research Council BB/P001262/1Medical Research Council MR/P028225/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/R001596/1
6 · The paper itself

Abstract

Mammalian infection models have contributed significantly to our understanding of the host-mycobacterial interaction, revealing potential mechanisms and targets for novel antimycobacterial therapeutics. However, the use of conventional mammalian models such as mice, are typically expensive, high maintenance, require specialized animal housing, and are ethically regulated. Furthermore, research using

Indexed as

Containment of BiohazardsDisease Models, AnimalAnimalsAnti-Bacterial AgentsDrug Evaluation, PreclinicalLarvaLuminescent MeasurementsMothsMycobacterium tuberculosisTuberculosisAnti-Bacterial Agentsantimycobacterial agentsauxotrophicdrug screeningGalleria mellonellainfection modelmycobacteriaMycobacterium tuberculosis complextuberculosis

Identifiers

PMID32530737
PMCPMC7550006
OpenAlexW3035307597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.